Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
J Immunol Res. 2018 Nov 27;2018:9473243. doi: 10.1155/2018/9473243. eCollection 2018.
Signaling through coinhibitory receptors downregulates the immune response to prevent excessive immune activation and maintain optimal immunity and tolerance. The aim of this study was to examine the levels of the soluble forms of coinhibitory receptors and their ligands, namely, galectin-9 (the ligand of T-cell immunoglobulin and mucin domain 3) and CD155 (the ligand of T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain), and their association with clinical features in patients with systemic sclerosis (SSc). The serum levels of galectin-9 and soluble sCD155 were examined by enzyme-linked immunosorbent assays in patients with SSc, and the results were evaluated with respect to clinical features. Patients with SSc exhibited raised serum levels of galectin-9, but not sCD155. Serum galectin-9 levels were raised not only in patients with diffuse cutaneous SSc but also in patients with limited cutaneous SSc. Furthermore, serum galectin-9 levels correlated positively with the erythrocyte sedimentation rate. In addition, increased serum galectin-9 levels tended to be associated with higher mortality and serious organ involvement. These results suggest that galectin-9, but not CD155, may be involved in the pathogenesis of SSc. In addition, the measurement of serum galectin-9 levels could be used to predict serious organ involvement and high mortality in patients with SSc.
通过抑制性受体信号转导可下调免疫应答，以防止过度的免疫激活，并维持最佳的免疫和耐受。本研究旨在检测可溶性抑制性受体及其配体（即半乳糖凝集素-9（T 细胞免疫球蛋白和粘蛋白结构域 3 的配体）和 CD155（T 细胞免疫球蛋白和免疫受体酪氨酸抑制基序结构域的配体）的水平及其与系统性硬化症（SSc）患者临床特征的相关性。通过酶联免疫吸附试验检测 SSc 患者血清中半乳糖凝集素-9 和可溶性 sCD155 的水平，并根据临床特征进行评估。SSc 患者的血清半乳糖凝集素-9 水平升高，但 sCD155 水平没有升高。弥漫性皮肤型 SSc 和局限性皮肤型 SSc 患者的血清半乳糖凝集素-9 水平均升高。此外，血清半乳糖凝集素-9 水平与红细胞沉降率呈正相关。此外，升高的血清半乳糖凝集素-9 水平可能与较高的死亡率和严重的器官受累有关。这些结果表明，半乳糖凝集素-9 而非 CD155 可能参与 SSc 的发病机制。此外，血清半乳糖凝集素-9 水平的测定可用于预测 SSc 患者严重的器官受累和高死亡率。
